Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.

J.J. Knox; C.H. Barrios; T.M. Kim; T. Cosgriff; V. Srimuninnimit; K. Pittman; R. Sabbatini; S.Y. Rha; T.W. Flaig; R.D. Page; J.T. Beck; F. Cheung; S. Yadav; P. Patel; L. Geoffrois; J. Niolat; N. Berkowitz; M. Marker; D. Chen; R.J. Motzer

doi:10.1093/ANNONC/MDX075

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.

J.J. Knox
, C.H. Barrios
, T.M. Kim
, T. Cosgriff
, V. Srimuninnimit
, K. Pittman
, R. Sabbatini
, S.Y. Rha
, T.W. Flaig
, R.D. Page
, J.T. Beck
, F. Cheung
, S. Yadav
, P. Patel
, L. Geoffrois
, J. Niolat
, N. Berkowitz
, M. Marker
, D. Chen
, R.J. Motzer

Princess Margaret Cancer Centre
Pontifícia Universidade Católica do Rio Grande do Sul
Seoul National University Hospital
Crescent City Research Consortium, Marrero, USA.
Mahidol University
Medical Oncology, The Queen Elizabeth Hospital, Woodville, Australia.
AOU Policlinico di Modena, Modena, Italy
Yonsei University
University of Colorado Denver
The Center for Cancer and Blood Disorders, Fort Worth.
Highlands Oncology Group, Fayetteville, USA.
Department of Oncology, Queen Elizabeth Hospital, Hong Kong, China.
University of Saskatchewan
University of Nottingham
Department of Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre Lès Nancy.
Novartis
Memorial Sloan-Kettering Cancer Center

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Annals of Oncology
Volume	28
Issue number	6
DOIs	https://doi.org/10.1093/ANNONC/MDX075
State	Published - Jun 1 2017
Externally published	Yes

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1093/ANNONC/MDX075License: Unspecified

Cite this

Knox, J. J., Barrios, C. H., Kim, T. M., Cosgriff, T., Srimuninnimit, V., Pittman, K., Sabbatini, R., Rha, S. Y., Flaig, T. W., Page, R. D., Beck, J. T., Cheung, F., Yadav, S., Patel, P., Geoffrois, L., Niolat, J., Berkowitz, N., Marker, M., Chen, D., & Motzer, R. J. (2017). Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Annals of Oncology, 28(6). https://doi.org/10.1093/ANNONC/MDX075

Knox, JJ, Barrios, CH, Kim, TM, Cosgriff, T, Srimuninnimit, V, Pittman, K, Sabbatini, R, Rha, SY, Flaig, TW, Page, RD, Beck, JT, Cheung, F, Yadav, S, Patel, P, Geoffrois, L, Niolat, J, Berkowitz, N, Marker, M, Chen, D & Motzer, RJ 2017, 'Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.', Annals of Oncology, vol. 28, no. 6. https://doi.org/10.1093/ANNONC/MDX075

@article{67b7e6c43f6d47f197a5626e37980dc5,

title = "Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.",

author = "J.J. Knox and C.H. Barrios and T.M. Kim and T. Cosgriff and V. Srimuninnimit and K. Pittman and R. Sabbatini and S.Y. Rha and T.W. Flaig and R.D. Page and J.T. Beck and F. Cheung and S. Yadav and P. Patel and L. Geoffrois and J. Niolat and N. Berkowitz and M. Marker and D. Chen and R.J. Motzer",

year = "2017",

month = jun,

day = "1",

doi = "10.1093/ANNONC/MDX075",

language = "American English",

volume = "28",

journal = "Annals of Oncology",

issn = "1569-8041",

publisher = "Elsevier",

number = "6",

}

TY - JOUR

T1 - Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.

AU - Knox, J.J.

AU - Barrios, C.H.

AU - Kim, T.M.

AU - Cosgriff, T.

AU - Srimuninnimit, V.

AU - Pittman, K.

AU - Sabbatini, R.

AU - Rha, S.Y.

AU - Flaig, T.W.

AU - Page, R.D.

AU - Beck, J.T.

AU - Cheung, F.

AU - Yadav, S.

AU - Patel, P.

AU - Geoffrois, L.

AU - Niolat, J.

AU - Berkowitz, N.

AU - Marker, M.

AU - Chen, D.

AU - Motzer, R.J.

PY - 2017/6/1

Y1 - 2017/6/1

UR - https://ir.ymlib.yonsei.ac.kr/bitstream/22282913/160952/1/T201703713.pdf

U2 - 10.1093/ANNONC/MDX075

DO - 10.1093/ANNONC/MDX075

M3 - Article

SN - 1569-8041

VL - 28

JO - Annals of Oncology

JF - Annals of Oncology

IS - 6

ER -

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.

Disciplines

Access to Document

Other files and links

Cite this